Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Sprout Health vs Modern Age

Two GLP-1 desks, one scoreboard. We put Sprout Health and Modern Age head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 6 · Grade B

Sprout Health

Visit Sprout Health Full brief →
vs
No. 392 · Grade C

Modern Age

Visit Modern Age Full brief →

The verdict

Sprout Health takes this head-to-head.

Sprout Health scores 86 to 56 on our six-factor Brief Score — A LegitScript-certified desk that pairs low-cost compounded semaglutide and tirzepatide with a real brand-name Wegovy and Zepbound path — and a near-frictionless, often visit-free start.

That doesn't make Modern Age a bad call — it's best for patients wanting a premium, branded-glp-1 weight program inside a longevity clinic. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
90
52
Supply Reliability
82
69
Transparency
88
24
Access Breadth
92
46
Clinical Oversight
78
83
Track Record
84
75
Sprout HealthBrief Score 86 · 56Modern Age

Price, coverage & the tracker

Sprout HealthModern Age
Brief Score86/100 (B)56/100 (C)
Semaglutide$149/moFrom $900/mo (all doses, medication billed separately, brand-name)
Tirzepatide$199/moNot disclosed
CoverageNot disclosedCoverage not published
Brand-name accessYesYes
Oral / sublingualInjection onlyInjection only
On the trackerStableprice stableNewnew to the tracker, no prior reading

Sprout Health: Compounded $149 semaglutide / $199 tirzepatide held flat this cycle, with a brand-name Wegovy/Zepbound path available on the same account.

Modern Age: New to the tracker on 1 August 2026. The published line reads From $900/mo (all doses, medication billed separately, brand-name) at our first reading; there is no earlier reading of ours to compare it against yet.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.